HR+/HER2- ADVANCED BREAST CANCER
Clinical trials for HR+/HER2- ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to stall breast cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs—entinostat and oral paclitaxel—in 50 people with HR-positive, HER2-negative advanced breast cancer who have already tried 2 to 4 prior treatments. The goal is to see if the combo can delay cancer growth. Participants take both d…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for advanced breast cancer? Triple-Drug combo tested after key therapy fails
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs (neratinib, fulvestrant, and eribulin) in 35 women with a specific type of advanced breast cancer (HR+/HER2+) that has stopped responding to the drug trastuzumab deruxtecan. The goal is to see if this new combination can shrin…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for advanced breast cancer: drug combo aims to halt tumor growth
Disease control Not yet recruitingThis study tests whether adding entinostat to fulvestrant can help control advanced breast cancer in people whose disease has worsened after standard hormone therapy and CDK4/6 inhibitors. About 50 women aged 18-75 with HR+/HER2- cancer will receive the combination. The main goal…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC